NCT05108883 - Risk Stratification Using Midregional Proadrenomedullin in the ED | Biotech Hunter

Enrollment

463

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

November 7, 2023

Study Completion Date

November 7, 2023

Conditions

Patients Presenting With Suspicion of Infection to the ED

Interventions

DEVICE

MR-proADM KRYPTOR

MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized

Trial Locations (9)

Hospital Clinico San Carlos, Madrid

Hospital Universitario Central de Asturias (HUCA), Oviedo

Hospital Santa Maria della Misericordia, Udine

Hospital Virgen de la Macarena, Seville

Hôpital Pitié-Salpêtrière, AP-HP.Sorbonne Université, Paris

Policlinico Tor Vergata, Roma

Hospital Clinic, Barcelona

Hampshire Hospitals NHS Foundation Trust, Basingstoke

University Hospital Southampton NHS Foundation Trust, Southampton

All Listed Sponsors

lead

Brahms AG

INDUSTRY